Skip to main content
Premium Trial:

Request an Annual Quote

Celera Sued Over Plans to Sell to Quest

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – The New Orleans Employees Retirement System is suing Celera, alleging its plan to sell the company to Quest Diagnostics for $671 million undervalues the company.

Along with Celera, its CEO, Kathy Ordoñez, and its board of directors are named as defendants in the lawsuit filed in Delaware Chancery Court. Quest and its wholly owned subsidiary, Spark Acquisition, are also named as defendants.

According to a report yesterday from Bloomberg, the New Orleans Employees Retirement System alleges that the price being paid by Quest is less than what Celera is worth after restating some financial figures, and that Celera's board failed to fulfill its fiduciary duties. The company's current high share price is evidence that Celera's board did not maximize the value of the firm, the plaintiffs alleged.

In late afternoon trading Thursday, shares of Celera on the Nasdaq were up 2 percent at $8.36. On March 17, the day before Quest's bid for Celera was announced, Celera's shares closed at $6.27.

David Speechly, a spokesman for Celera, said the company had no comment on the lawsuit.

The Scan

Study Links Evolution of Longevity, Social Organization in Mammals

With the help of comparative phylogenetics and transcriptomics, researchers in Nature Communications see ties between lifespan and social organization in mammals.

Tumor Microenvironment Immune Score Provides Immunotherapy Response, Prognostic Insights

Using multiple in situ analyses and RNA sequence data, researchers in eBioMedicine have developed a score associated with immunotherapy response or survival.

CRISPR-Based Method for Finding Cancer-Associated Exosomal MicroRNAs in Blood

A team from China presents in ACS Sensors a liposome-mediated membrane fusion strategy for detecting miRNAs carried in exosomes in the blood with a CRISPR-mediated reporter system.

Drug Response Variants May Be Distinct in Somatic, Germline Samples

Based on variants from across 21 drug response genes, researchers in The Pharmacogenomics Journal suspect that tumor-only DNA sequences may miss drug response clues found in the germline.